Abstract
The degree of Helicobacter pylori (H. pylori) infection is the most important factor affecting gastrointestinal health and is influenced by the subjects' (age, gender, and geographic location). Because it can cling to a simple columnar epithelium with numerous tubular gastric glands and regulate the appearance of its specific virulence factor, H. pylori is a highly adaptable environmental bacteria. It's still unclear of the role cytokines function in stomach precancerous disorders. It leads to the cause in one sense, but it also causes gastric precancerous lesions to occur in another. On the one hand, they can promote the development of disease by stimulating immune responses that the aim to eradicate pathogens. This study aimed to investigate the profile of some cytokines and the characteristics of cytokines parameters by H. pylori infection in chronic atrophic gastritis (CAG). An increase in IL-2 was observed in H. pylori-containing Chronic Gastritis (CG) and H. pylori-containing CAG, which may contribute to increased cytotoxic lymphocyte destruction and the achievement of antitumor effects. A decrease in phagocyte activity and an increase in the absolute number of band neutrophils in peripheral blood are the results of hyperproduction of IL-8 and Chronic Atrophic Gastritis (CAG) with H. pylori, indicating altered host defense mechanisms. Major Histocompatibility Complex (MHC) molecules on antigen-presenting cells are expressed more highly, and the amount of IFNγ involved in recognizing malignantly transformed cells is increased. H. pylori with (Chronic Gastritis (CG) and CAG) in patients showed an increase in the cytokine IL-4 production, which may be a factor in the chronicity of H. pylori-associated diseases. This study establishes an experimental foundation for future research on the eradication of H. pylori and the immunological causes of Chronic Gastritis (CG) and CAG.
References
1.Ilina A.E., Stanislav M.L., Denisov L.N. Interleukin 1 as a mediator of inflammation and therapeutic target. Nauchno prakticheskaya revmatologiya = Rheumatology Science and Practice, 2011, no. 3, pp. 62–71.
2.Kozlov V.K. Cytokine therapy: pathogenetic orientation in infectious diseases and clinical efficacy: a guide for physicians. St. Petersburg: Alter Ego, 2010. 148.
3.Shtygasheva O.V. Ageeva E.S. Iptyshev V.M. The role of immunoregulatory cytokines in the pathogenesis of chronic gastritis and peptic ulcer disease, the search for predictors of diseases. Sibirskiy meditsinskiy zhurnal = Siberian Medical Journal, 2011, no. 1, pp. 88–90.
4.Wang R, Chen XZ. Prevalence of atrophic gastritis in southwest China and predictive strength of serum gastrin‐ 17: a cross‐sectional study (SIGES). Sci Rep. 2020;10(1):4523.
5.Souissi S, Makni C, Belhadj Ammar L, Bousnina O, Kallel L. Correlation between the intensity of Helicobacter pylori colonization and severity of gastritis: results of a prospective study. Helicobacter. 2022;27:e12910.
6.Piccinni MP, Raghupathy R, Saito S, Szekeres‐Bartho J. Cytokines, hormones and cellular regulatory mechanisms favoring successful reproduction. Front Immunol. 2021;12:717808.
7.Azer SA, Akhondi H. Gastritis. In: StatPearls. Treasure Island (FL): Stat Pearls Publishing; July 4, 2022. PMID: 31334970, Bookshelf ID: NBK544250.
8.Sharndama HC, Mba IE. Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms. Braz J Microbiol. 2022;53(1):33-50. https://doi.org/10.1007/s42770-021-00675-0.
9.Leja M, Grinberga-Derica I, Bilgilier C, Steininger C. Review: Epidemiology of Helicobacter pylori infection. Helicobacter. 2019 Sep;24 Suppl 1:e12635. https://doi.org/10.1111/hel.12635. PMID: 31486242.
10.Camilo V, Sugiyama T, Touati E. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2017; 22(suppl 1):e12405.
11.Gong J, Zhan H, Liang Y, He Q, Cui D. Role of Th22 cells in human viral diseases. Front Med. 2021; 8:708140.
12.Yin X, Zhong L, Lin C, et al. Tojapride reverses esophageal epithelial inflammatory responses on reflux esophagitis model rats. Chin J Integr Med. 2021; 27(8): 604-612.
13.Salvatori S, Marafini I, Laudisi F, Monteleone G, Stolfi C. Helicobacter pylori and gastric cancer: pathogenetic mechanisms. Int J Mol Sci. 2023;24(3):2895. doi: 10.3390/ijms24032895.
14.Sukri A, Hanafiah A, Mohamad Zin N, Kosai NR. Epidemiology and role of Helicobacter pylori virulence factors in gastric cancer carcinogenesis. APMIS. 2020;128(2):150–161.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Medicina Internacia Revuo